The gout drug candidate BioCryst (NASDAQ:BCRX) is developing now has the green light to advance into phase 3 clinical trials, but some of the best news CEO Jon Stonehouse heard recently came from business deals that did not even involve the company. AstraZeneca (NYSE:AZN) announced it would acquire Ardea BioSciences for $1.26 billion; Takeda Pharmaceutical […]
A new gout treatment being developed by BioCryst (NASDAQ:BCRX) has achieved positive phase 2 clinical trial results, which support the advance of the drug candidate into late-stage clinical studies and boost the company’s case for finding a drug partner to take on the compound. BioCryst, a Durham, North Carolina-based biopharmaceutical company, is studying the compound […]
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
The investigational gout treatment being developed by BioCryst Pharmaceuticals (NASDAQ:BCRX) aims to take an old gout drug and make it work better. Most gout patients are treated with the nearly 50-year-old drug allopurinol, which is used to reduce the levels of uric acid that cause the painful inflammation of gout. But fewer than half of […]
North Carolina biotechnology company BioCryst (NASDAQ:BCRX) remains on schedule developing its various drug programs and the company is well capitalized. CEO Jon Stonehouse said the company’s $72 million in cash is enough to last the company two years. Yet on a morning that saw the company disclose nothing remotely controversial during its quarterly conference call, […]
The NC biotech BioCryst (NASDAQ:BCRX) is turning to Wall Street as another way to stockpile cash. According to a U.S. Securities and Exchange Commission filing Tuesday, the Durham drug company can raise up to $70 million by selling additional common stock and other securities. This is the latest of several fund-raising efforts by the company […]
An NC biotech company developing a new flu treatment has named healthcare venture capital veteran Kenneth Lee to its board of directors. Lee, a general partner with Durham, North Carolina, venture capital firm Hatteras Venture Partners, brings to BioCryst (NASDAQ:BCRX) more than 35 years of experience counseling technology companies. Durham-based BioCryst’s lead drug candidate is […]
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
GlaxoSmithKline (NYSE:GSK) is coughing up $39 million to buy the remaining stake in a joint venture company formed to make flu vaccines in China. The pharmaceutical giant, which has its U.S. headquarters in Research Triangle Park, North Carolina, announced it has entered into an agreement to acquire the 51 percent stake in Shenzhen Neptunus Interlong […]
BioCryst Pharmaceuticals CEO Jon Stonehouse got a jump on Memorial Day weekend travel. Today, Stonehouse is in London where he will tell European doctors and healthcare professionals how BioCryst’s experimental gout drug can pair with a nearly 50-year-old gout treatment and make it work significantly better. Stonehouse is presenting at the Annual European Congress of […]
BioCryst Pharmaceuticals (NASDAQ:BCRX) has hired former Inspire Pharmaceuticals executive Tom Staab to become the drug developer’s new CFO. Staab starts with Durham, North Carolina-based BioCryst on July 1. Current BioCryst CFO Stuart Grant has agreed to extend his employment an additional month until then. Staab has been executive vice president, CFO and treasurer of Inspire […]
BioCryst Pharmaceuticals (NASDAQ:BCRX) got its hands on some big dollars in the first three months of 2011, securing $55 million from a federal contract for its experimental flu treatment peramivir and net proceeds of $23 million through a deal with a Japanese partner. But here’s a number that might have slipped under the radar — […]
Help shape the future of healthcare benefits by sharing your insights.
BioCryst Pharmaceuticals has secured $30 million in new financing through a deal with its Japanese drug partner. BioCryst will use the money for continued R&D.
The NC biotech won proposed changes to federal funding that triggered this new infusion of cash. BioCryst Pharmaceuticals' additional $55 million for flu treatment clinical trials and a new drug application is "money that will get us to the finish line," CEO Jon Stonehouse said.
BioCryst Pharmaceuticals Chief Financial Officer Stuart Grant is resigning from the Durham, North Carolina, company to spend more time with his family following the loss of his son last year.
Drug developer BioCryst Pharmaceuticals wants to expand the phase III clinical trial for its experimental flu treatment peramivir, but the changes could mean delays for developing the anti-viral drug.